{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:25:08Z","timestamp":1794900308324,"version":"4.9.1"},"reference-count":218,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome is driven by the interplay of visceral adiposity, insulin resistance, chronic inflammation, oxidative stress, and progressive kidney dysfunction. These mechanisms generate a distinct atherogenic dyslipidaemic phenotype characterised by elevated triglycerides (TG), reduced high-density lipoprotein-cholesterol (HDL-C), increased apolipoprotein B (apoB)-containing lipoproteins, remnant cholesterol (RC) accumulation, small dense low-density lipoprotein (LDL) particles, and frequently elevated lipoprotein(a) [Lp(a)]. Such lipid abnormalities contribute to accelerated atherosclerosis and early renal deterioration. In turn, kidney dysfunction further amplifies lipid abnormalities. These pathways underscore the need for a timely and comprehensive lipid assessment using apoB, non-HDL-C, RC, and Lp(a) within the CKM framework. Effective lipid management is crucial for CKM syndrome treatment, with the potential to reduce residual cardiovascular and renal risk and improve long-term clinical outcomes. In this narrative review, we examine current evidence on the pathophysiological mechanisms underlying CKM-related dyslipidaemia and provide a practical framework for its assessment and management. Management requires a multimodal approach tailored to the patient\u2019s lipid phenotype and overall cardiovascular risk, incorporating a range of lipid-lowering strategies including statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, fibrates, icosapent ethyl, and emerging therapies targeting apoC-III, ANGPTL3, and Lp(a). Beyond lipid lowering, lifestyle interventions and cardiometabolic therapies such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and finerenone may provide complementary cardiometabolic and renal protection.<\/jats:p>","DOI":"10.3390\/ijms27188317","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:18:26Z","timestamp":1790860706000},"page":"8317","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Features of Lipid Disorders in Cardiovascular\u2013Kidney\u2013Metabolic Syndrome"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-9051","authenticated-orcid":false,"given":"Alexandr","family":"Ceasovschih","sequence":"first","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-5133","authenticated-orcid":false,"given":"Yusuf Ziya","family":"\u015eener","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thoraxcentrum, Erasmus MC, 3015 CE\u00a0Rotterdam, The Netherlands"},{"name":"Department of Internal Medicine, Yavuzeli District State Hospital, 27907\u00a0Gaziantep, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Arici","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hacettepe University, 06800 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariia","family":"Cherska","sequence":"additional","affiliation":[{"name":"State Institution \u201cV.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine\u201d, 04114 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bianconi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1583-6567","authenticated-orcid":false,"given":"Malik","family":"Ejubovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cantonal Hospital Zenica, 72000 Zenica, Bosnia and Herzegovina"},{"name":"University of Zenica, 72000 Zenica, Bosnia and Herzegovina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7083-2692","authenticated-orcid":false,"given":"Stanislav","family":"Kotlyarov","sequence":"additional","affiliation":[{"name":"Department of Nursing, Ryazan State Medical University, 390026 Ryazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1327-1059","authenticated-orcid":false,"given":"Vladimir","family":"Ristovski","sequence":"additional","affiliation":[{"name":"Department for Invasive and Interventional Cardiology, City General Hospital \u201c8th of September\u201d, 1000 Skopje, North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-5355","authenticated-orcid":false,"given":"Ahmet","family":"Yetkin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Su\u015fehri District State Hospital, 58600 Sivas, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7543-4167","authenticated-orcid":false,"given":"Pelin","family":"Golforoush","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9158-2012","authenticated-orcid":false,"given":"Tatyana","family":"Storozhenko","sequence":"additional","affiliation":[{"name":"Cardiovascular Center Aalst, 9300 Aalst, Belgium"},{"name":"Department of Prevention and Treatment of Emergency Conditions, L.T. Malaya Therapy National Institute NAMSU, 61039 Kharkiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-6895","authenticated-orcid":false,"given":"Fotios","family":"Barkas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-436X","authenticated-orcid":false,"given":"Alexandru","family":"Corlateanu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, State University of Medicine and Pharmacy \u201cNicolae Testemitanu\u201d, 2004 Chisinau, Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8620-3655","authenticated-orcid":false,"given":"Pradeesh","family":"Sivapalan","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark"},{"name":"Copenhagen Respiratory Research, Department of Medicine, Copenhagen University Hospital\u2014Herlev and Gentofte, DK-2900 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9839-0718","authenticated-orcid":false,"given":"Tea","family":"Gamezardashvili","sequence":"additional","affiliation":[{"name":"Remedical Hospital, 9\/16\u2019 Tsinandali Str., 1044 Tbilisi, Georgia"},{"name":"Georgian Atherosclerosis Association, 9\u2019 L. Managadze Str., 0144 Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio M.","family":"Gotto","sequence":"additional","affiliation":[{"name":"Weill Medical College, Cornell University, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentiu","family":"Sorodoc","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victorita","family":"Sorodoc","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1016\/j.jacc.2026.03.056","article-title":"2026 AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Ndumele","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIR.0000000000001457","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Blumenthal","year":"2026","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/dom.15485","article-title":"Inter-relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management","volume":"26","author":"Vora","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6691516","DOI":"10.1155\/mi\/6691516","article-title":"Association of Three Composite Inflammatory and Lipid Metabolism Indicators with Cardiovascular-Kidney-Metabolic Syndrome: A Cross-Sectional Study Based on NHANES 1999\u20132020","volume":"2025","author":"Song","year":"2025","journal-title":"Mediat. Inflamm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e3755","DOI":"10.1002\/dmrr.3755","article-title":"Cardio-renal-metabolic disease in primary care setting","volume":"40","author":"Ibrahim","year":"2024","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102344","DOI":"10.1016\/j.cpcardiol.2023.102344","article-title":"Cardiovascular-kidney-metabolic (CKM) syndrome: A state-of-the-art review","volume":"49","author":"Sebastian","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(25)01384-4","article-title":"Cardiovascular, kidney, and metabolic health: An actionable vision for heart failure prevention","volume":"406","author":"Ostrominski","year":"2025","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1152\/ajpcell.00499.2025","article-title":"Cardiovascular-kidney-metabolic syndrome: Prevalence, risks, disease trajectories, and early-stage management","volume":"330","author":"Gunnarsson","year":"2026","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10157-013-0881-x","article-title":"In Vivo Kinetic Studies to Further Understand Pathogenesis of Abnormal Lipoprotein Metabolism in Chronic Kidney Disease","volume":"18","author":"Ikewaki","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12944-026-02862-0","article-title":"Hypertriglyceridemia in Chronic Kidney Disease: Pathophysiological Mechanisms, Cardiovascular Risk, and Emerging Therapeutics","volume":"25","author":"Li","year":"2026","journal-title":"Lipids Health Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-026-01399-y","article-title":"Apolipoprotein C-III: Risk-Factor, Regulator of Triglyceride-Rich Lipoprotein Metabolism and Therapeutic Target","volume":"28","author":"Adiels","year":"2026","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1874192401105010041","article-title":"Dyslipidemia Associated with Chronic Kidney Disease","volume":"5","author":"Tsimihodimos","year":"2011","journal-title":"Open Cardiovasc. Med. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"120563","DOI":"10.1016\/j.atherosclerosis.2025.120563","article-title":"Lipid Lowering Therapies in Chronic Kidney Disease: A Call to Action","volume":"411","author":"Arroyo","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1194\/jlr.M011163","article-title":"Plasma Apolipoprotein C-III Metabolism in Patients with Chronic Kidney Disease","volume":"52","author":"Ooi","year":"2011","journal-title":"J. Lipid Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2369701","DOI":"10.1080\/0886022X.2024.2369701","article-title":"Estimated Small Dense Low-Density Lipoprotein-Cholesterol and the Risk of Kidney and Cardiovascular Outcomes in Diabetic Kidney Disease","volume":"46","author":"Yang","year":"2024","journal-title":"Ren. Fail."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/jdi.14398","article-title":"Clinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Measurement in Type 2 Diabetes","volume":"16","author":"Hirano","year":"2025","journal-title":"J. Diabetes Investig."},{"key":"ref_17","first-page":"847","article-title":"Small Dense Low-Density Lipoprotein Cholesterol and Renal Function: A Missing Link in Cardiovascular Risk Assessment for Chronic Kidney Disease Patients","volume":"89","author":"Ito","year":"2025","journal-title":"Circ. J. Off. J. Jpn. Circ. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"108950","DOI":"10.1016\/j.maturitas.2026.108950","article-title":"Association of Small Dense Low-Density Lipoprotein Cholesterol with Longitudinal Trajectories of Cardio-Kidney-Metabolic Comorbidity: A Prospective Cohort Study Based on Multi-State Markov Models","volume":"209","author":"Wang","year":"2026","journal-title":"Maturitas"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.ki.5002240","article-title":"Evidence Mounts for a Role of the Kidney in Lipoprotein(a) Catabolism","volume":"71","author":"Albers","year":"2007","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and Consequences of Lipoprotein(a) Abnormalities in Kidney Disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The Role of Lipoprotein(a) in Chronic Kidney Disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"sfae032","DOI":"10.1093\/ckj\/sfae032","article-title":"Renal Function Alters the Association of Lipoprotein(a) with Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Prospective Cohort Study","volume":"17","author":"Zeng","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/joim.20027","article-title":"Lipoprotein(a) Concentrations and Cardiovascular Disease in Patients with Chronic Kidney Disease: Results from the German Chronic Kidney Disease Study","volume":"296","author":"Gruber","year":"2024","journal-title":"J. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1111\/dom.16258","article-title":"Association between Remnant Cholesterol and Chronic Kidney Disease: Systematic Review and Meta-analysis","volume":"27","author":"Karakasis","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"25985","DOI":"10.31083\/RCM25985","article-title":"Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease","volume":"26","author":"Li","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/eurjpc\/zwaf248","article-title":"Association between Remnant Cholesterol and the Risk of Cardiovascular-Kidney-Metabolic Syndrome Progression: Insights from the China Health and Retirement Longitudinal Study","volume":"32","author":"Ding","year":"2025","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_27","first-page":"672","article-title":"Remnant Cholesterol Inflammatory Index and Mortality in Cardiovascular-Kidney-Metabolic Syndrome: A National Study","volume":"22","author":"Wang","year":"2026","journal-title":"Arch. Med. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1038\/s41598-025-32281-7","article-title":"Remnant Cholesterol Inflammatory Index and Cardiovascular Disease among Adults with Cardiovascular-Kidney-Metabolic Syndrome Stages 0\u20133: A Nationwide Prospective Cohort Study","volume":"16","author":"Yang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e025858","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological Bases for the Superiority of Apolipoprotein B over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e647\u201363","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus from the National Lipid Association","volume":"18","author":"Soffer","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Katsi, V., Argyriou, N., Fragoulis, C., and Tsioufis, K. (2025). The Role of Non-HDL Cholesterol and Apolipoprotein B in Cardiovascular Disease: A Comprehensive Review. J. Cardiovasc. Dev. Dis., 12.","DOI":"10.3390\/jcdd12070256"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among ApoB, Non-High-Density Lipoprotein Cholesterol, and Triglycerides: Implications for Cardiovascular Prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.124.068885","article-title":"Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice","volume":"150","author":"Joshi","year":"2024","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mazidi, M., Webb, R.J., Lip, G.Y.H., Kengne, A.P., Banach, M., and Davies, I.G. (2022). Discordance between LDL-C and Apolipoprotein B Levels and Its Association with Renal Dysfunction: Insights from a Population-Based Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11020313"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Baragetti, A., Ossoli, A., Strazzella, A., Simonelli, S., Baragetti, I., Grigore, L., Pellegatta, F., Catapano, A.L., Norata, G.D., and Calabresi, L. (2020). Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072289"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1053\/j.ajkd.2015.06.028","article-title":"Cholesterol Metabolism in CKD","volume":"66","author":"Reiss","year":"2015","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"41481","DOI":"10.1038\/srep41481","article-title":"High Density Lipoprotein (HDL) Particles from End-Stage Renal Disease Patients Are Defective in Promoting Reverse Cholesterol Transport","volume":"7","author":"Anderson","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Marsche, G., Heine, G.H., Stadler, J.T., and Holzer, M. (2020). Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease. Biomolecules, 10.","DOI":"10.3390\/biom10091348"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2010111144","article-title":"Uremia Alters HDL Composition and Function","volume":"22","author":"Holzer","year":"2011","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2011070668","article-title":"Serum Amyloid A in Uremic HDL Promotes Inflammation","volume":"23","author":"Weichhart","year":"2012","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1681\/ASN.V9112082","article-title":"Decrease of Serum Paraoxonase Activity in Chronic Renal Failure","volume":"9","author":"Dantoine","year":"1998","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41586-021-04064-3","article-title":"The power of genetic diversity in genome-wide association studies of lipids","volume":"600","author":"Graham","year":"2021","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"111134","DOI":"10.1016\/j.isci.2024.111134","article-title":"A Multiorgan Map of Metabolic, Signaling, and Inflammatory Pathways That Coordinately Control Fasting Glycemia in Mice","volume":"27","author":"Mehl","year":"2024","journal-title":"iScience"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s43152-024-00056-3","article-title":"Cellular and Molecular Mechanisms of Insulin Resistance","volume":"5","author":"Chandrasekaran","year":"2024","journal-title":"Curr. Tissue Microenviron. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2337\/dbi20-0028","article-title":"A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement Lecture","volume":"70","author":"Ferrannini","year":"2021","journal-title":"Diabetes"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12933-025-02860-z","article-title":"Insulin Resistance Assessed by Estimated Glucose Disposal Rate Predicts Cardiovascular Disease in Stages 0\u20133 of Cardiovascular-Kidney-Metabolic Syndrome: A UK Biobank Cohort Study","volume":"24","author":"Zhang","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zaitoon, H., Abdul-Ghani, M., and DeFronzo, R.A. (2026). Insulin Resistance and Hyperinsulinaemia in Kidney Disease: Mechanisms and Metabolic Effects. Nat. Rev. Nephrol., ahead of print.","DOI":"10.1038\/s41581-026-01066-0"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s43556-026-00486-5","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenesis and Novel Treatment Options","volume":"7","author":"Ren","year":"2026","journal-title":"Mol. Biomed."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/ATVBAHA.111.241463","article-title":"Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia","volume":"32","author":"Sparks","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Cazac, G.D., L\u0103c\u0103tu\u0219u, C.M., Mihai, C., Grigorescu, E.D., Onofriescu, A., and Mihai, B.M. (2022). Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102375"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women with Nonalcoholic Fatty Liver Disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Chen, Y., Lei, K., Liu, Y., Liu, J., Wei, K., Guo, J., and Su, Z. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease: From a Very Low-Density Lipoprotein Perspective. Biomolecules, 15.","DOI":"10.3390\/biom15070990"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes. Facts, 17, 374\u2013444. Erratum in Obes. Facts\u00a02024, 17, 658. https:\/\/doi.org\/10.1159\/000541386.","DOI":"10.1159\/000539371"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in Obesity, Diabetes, and Related Disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11892-015-0670-x","article-title":"Adipose Tissue Inflammation in the Pathogenesis of Type 2 Diabetes","volume":"15","author":"Kohlgruber","year":"2015","journal-title":"Curr. Diabetes Rep."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Gerdanovics, C.-A., Suciu, \u0218.-M., Or\u0103\u0219an, O.-H., Para, I., Turi, V.-R., Milaciu, M.-V., Perne, M.-G., Cium\u0103rnean, L., Leach, N.-V., and Alexescu, T.-G. (2025). Adipokines and Vascular Modulators in CKM: Emerging Biomarkers as Diagnostic and Therapeutic Targets. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262211083"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kwon, H., and Pessin, J.E. (2013). Adipokines Mediate Inflammation and Insulin Resistance. Front. Endocrinol., 4.","DOI":"10.3389\/fendo.2013.00071"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1042\/CS20171107","article-title":"Altered microbiome in chronic kidney disease: Systemic effects of gut-derived uremic toxins","volume":"132","author":"Lau","year":"2018","journal-title":"Clin. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/advances\/nmab149","article-title":"Effects of Microbiota-Driven Therapy on Circulating Indoxyl Sulfate and P-Cresyl Sulfate in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"13","author":"Chen","year":"2022","journal-title":"Adv. Nutr."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"D\u2019Elia, J.A., and Weinrauch, L.A. (2024). Lipid Toxicity in the Cardiovascular-Kidney-Metabolic Syndrome (CKMS). Biomedicines, 12.","DOI":"10.3390\/biomedicines12050978"},{"key":"ref_61","first-page":"5478708","article-title":"Oxidative Stress in the Pathophysiology of Kidney Disease: Implications for Noninvasive Monitoring and Identification of Biomarkers","volume":"2020","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"31152","DOI":"10.1038\/s41598-025-17173-0","article-title":"Association between C-Reactive Protein-Triglyceride Glucose Index and Future Cardiovascular Disease Risk in a Population with Cardiovascular-Kidney-Metabolic Syndrome Stage 0\u20133","volume":"15","author":"Lu","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Florens, N., Calzada, C., Lyasko, E., Juillard, L., and Soulage, C.O. (2016). Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins. Toxins, 8.","DOI":"10.3390\/toxins8120376"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehu111","article-title":"Carbamylated Low-Density Lipoprotein Induces Endothelial Dysfunction","volume":"35","author":"Speer","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Saar-Kovrov, V., Pawlowska, A., Guillot, A., Gijbels, M.J.J., Sluimer, J.C., Temmerman, L., Goossens, P., Mees, B.M.E., Tacke, F., and Jankowski, V. (2025). Protein Carbamylation in Atherosclerotic Plaques Correlates with Uremia and Disease Progression, Localizing Predominantly to Foam Cells. Front. Immunol., 16, Correction in Front. Immunol.\u00a02025, 16, 1637511. https:\/\/doi.org\/10.3389\/fimmu.2025.1637511.","DOI":"10.3389\/fimmu.2025.1637511"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gonzalez-Plascencia, M., Garza-Veloz, I., Flores-Morales, V., and Martinez-Fierro, M.L. (2026). The Role of Ceramides in Metabolic and Cardiovascular Diseases. J. Cardiovasc. Dev. Dis., 13.","DOI":"10.3390\/jcdd13010030"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Yang, S., and Wu, Y. (2025). Ceramide Metabolism and Cardiovascular Risk Factors: Insights into Therapeutic Strategies. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1656113"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"100552","DOI":"10.1016\/j.jlr.2024.100552","article-title":"Association of Plasma Ceramide with Decline in Kidney Function in Patients with Type 2 Diabetes","volume":"65","author":"Gurung","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"101152","DOI":"10.1016\/j.diabet.2020.03.003","article-title":"Association between Increased Plasma Ceramides and Chronic Kidney Disease in Patients with and without Ischemic Heart Disease","volume":"47","author":"Mantovani","year":"2021","journal-title":"Diabetes Metab."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Chen, Q., Li, X., Xie, Y., Li, Y., Sheng, Z., Che, W., An, S., Fu, S., He, L., and Fang, C. (2026). Chronic Kidney Disease, Circulating Ceramides and Coronary Microvascular Dysfunction: Insights from the CRUISE-MET Study. Cardiorenal Med., 1\u201320.","DOI":"10.1159\/000552268"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00125-012-2649-3","article-title":"Regulation of Plasma Ceramide Levels with Fatty Acid Oversupply: Evidence That the Liver Detects and Secretes De Novo Synthesised Ceramide","volume":"55","author":"Watt","year":"2012","journal-title":"Diabetologia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1874312901206010123","article-title":"Sphingolipid Regulation of Tissue Fibrosis","volume":"6","author":"Shea","year":"2012","journal-title":"Open Rheumatol. J."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Nicholson, R.J., Pezzolesi, M.G., and Summers, S.A. (2021). Rotten to the Cortex: Ceramide-Mediated Lipotoxicity in Diabetic Kidney Disease. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.622692"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"\u0160aki\u0107, Z., Ati\u0107, A., Poto\u010dki, S., and Ba\u0161i\u0107-Juki\u0107, N. (2024). Sphingolipids and Chronic Kidney Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175050"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"41231","DOI":"10.1038\/srep41231","article-title":"Mechanistic Interplay between Ceramide and Insulin Resistance","volume":"7","author":"Reali","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Sokolowska, E., and Blachnio-Zabielska, A. (2019). The Role of Ceramides in Insulin Resistance. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00577"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Janssen, J.A.M.J.L. (2024). The Causal Role of Ectopic Fat Deposition in the Pathogenesis of Metabolic Syndrome. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413238"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3803\/EnM.2014.29.1.1","article-title":"Ectopic Fat Assessment Focusing on Cardiometabolic and Renal Risk","volume":"29","author":"Lim","year":"2014","journal-title":"Endocrinol. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1161\/01.CIR.0000099542.57313.C5","article-title":"Human Epicardial Adipose Tissue Is a Source of Inflammatory Mediators","volume":"108","author":"Mazurek","year":"2003","journal-title":"Circulation"},{"key":"ref_80","first-page":"416","article-title":"Epicardial Adipose Tissue: Far More than a Fat Depot","volume":"4","author":"Talman","year":"2014","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Wiszniewski, K., Grudniewska, A., Szab\u0142owska-Gadomska, I., Pilichowska-Paszkiet, E., Zaborska, B., Zgliczy\u0144ski, W., Dudek, P., Bik, W., Sota, M., and Mrozikiewicz-Rakowska, B. (2025). Epicardial Adipose Tissue\u2014A Novel Therapeutic Target in Obesity Cardiomyopathy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26167963"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e70098","DOI":"10.1111\/nep.70098","article-title":"Mitigating Lipotoxicity: A Potential Mechanism to Delay Chronic Kidney Disease Progression Using Current Pharmacological Therapies","volume":"30","author":"Anumas","year":"2025","journal-title":"Nephrology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/1753-0407.13232","article-title":"Fatty Kidney Disease: The Importance of Ectopic Fat Deposition and the Potential Value of Imaging","volume":"14","author":"Mende","year":"2022","journal-title":"J. Diabetes"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Gai, Z., Wang, T., Visentin, M., Kullak-Ublick, G.A., Fu, X., and Wang, Z. (2019). Lipid Accumulation and Chronic Kidney Disease. Nutrients, 11.","DOI":"10.3390\/nu11040722"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3680397","DOI":"10.1155\/2020\/3680397","article-title":"Recent Progress on Lipid Intake and Chronic Kidney Disease","volume":"2020","author":"Pei","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.P040501","article-title":"Altered Renal Lipid Metabolism and Renal Lipid Accumulation in Human Diabetic Nephropathy","volume":"55","author":"Scherzer","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and Validation of the American Heart Association\u2019s PREVENT Equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series","volume":"72","author":"Ference","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"107255","DOI":"10.1016\/j.vph.2023.107255","article-title":"Inflammation and the pathogenesis of atherosclerosis","volume":"154","author":"Libby","year":"2024","journal-title":"Vasc. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Jafar","year":"2021","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrneph.2015.180","article-title":"HDL abnormalities in nephrotic syndrome and chronic kidney disease","volume":"12","author":"Vaziri","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-024-00563-5","article-title":"Metabolic syndrome","volume":"10","author":"Neeland","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrneph.2009.184","article-title":"An update on the lipid nephrotoxicity hypothesis","volume":"5","author":"Ruan","year":"2009","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","article-title":"Disorders of lipid metabolism in nephrotic syndrome: Mechanisms and consequences","volume":"90","author":"Vaziri","year":"2016","journal-title":"Kidney Int."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrneph.2014.31","article-title":"Novel targets of antifibrotic and anti-inflammatory treatment in CKD","volume":"10","author":"Sharma","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"(2024). Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights from Epidemiology, Genetics, and Biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., and Keech, A. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: A patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"Glynn","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk","volume":"392","author":"Watts","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"Rosenson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran\u2014A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., and Mayne, K.J. (2023). Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40265-025-02158-0","article-title":"Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions","volume":"85","author":"Tramontano","year":"2025","journal-title":"Drugs"},{"key":"ref_125","first-page":"S26","article-title":"Medications for Lipid Control: Statins vs Newer Drugs","volume":"40","author":"McPherson","year":"2024","journal-title":"Can. J. Cardiol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Pirro, M., Simental-Mend\u00eda, L.E., Bianconi, V., Watts, G.F., Banach, M., and Sahebkar, A. (2019). Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET\/CT: A Systematic Review and Meta-Analysis of Interventional Studies. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010118"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/2047487313480435","article-title":"Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: A network meta-analysis of placebo-controlled and active-comparator trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: A meta-analysis","volume":"43","author":"Penson","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_130","first-page":"e38","article-title":"American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_131","first-page":"200141","article-title":"Revisiting cardiovascular risk reduction in type 2 diabetes and dyslipidemia","volume":"14","author":"Lim","year":"2022","journal-title":"Int. J. Cardiol. Cardiovasc Risk Prev."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Jardine","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40256-026-00793-w","article-title":"A Comprehensive, Updated Review of Ezetimibe: Evidence-Based Clinical Use for Atherosclerotic Cardiovascular Disease","volume":"26","author":"Liu","year":"2026","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Strikic, D., Begic, Z., Radman, I., Zlopasa, F., Mateljic, J., Zec, I., Titlic, M., Sliskovic, A.M., Pecin, I., and Reiner, Z. (2025). Reshaping Dyslipidaemia Treatment with Bempedoic Acid-A Narrative Review. Biomedicines, 13.","DOI":"10.3390\/biomedicines13061460"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"117182","DOI":"10.1016\/j.atherosclerosis.2023.06.973","article-title":"Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials","volume":"378","author":"Shapiro","year":"2023","journal-title":"Atherosclerosis"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/dom.14645","article-title":"Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials","volume":"24","author":"Leiter","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e037898","DOI":"10.1161\/JAHA.124.037898","article-title":"Bempedoic Acid for Prevention of Cardiovascular Events in People with Obesity: A CLEAR Outcomes Subset Analysis","volume":"14","author":"Bays","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"101645","DOI":"10.1016\/j.ajpc.2026.101645","article-title":"The impact of bempedoic acid on cardiovascular events across the spectrum of kidney function, a CLEAR Outcomes trial secondary analysis","volume":"28","author":"Zingano","year":"2026","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MOL.0000000000000601","article-title":"Proprotein convertase subtilisin\/kexin type 9 and lipid metabolism","volume":"30","author":"Spolitu","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14712598.2020.1677604","article-title":"PCSK9 inhibitors and cardiovascular outcomes","volume":"20","author":"Steffens","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in Patients without a Previous Myocardial Infarction or Stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"117444","DOI":"10.1016\/j.cca.2023.117444","article-title":"Insight into the role of PCSK9 in glucose metabolism","volume":"547","author":"Xu","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1016\/j.jacc.2025.10.036","article-title":"Obesity-Associated Cardiovascular Risk and Benefit from PCSK9 Inhibition: A Prespecified Analysis from FOURIER","volume":"87","author":"Kang","year":"2026","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Tang, H., Li, X., Wang, F., Liu, H., Zhang, X., Liu, B., and Wang, B. (2025). Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease. BMC Nephrol., 26.","DOI":"10.1186\/s12882-025-04347-1"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1353848","DOI":"10.3389\/fphar.2024.1353848","article-title":"Association between PCSK9 inhibitors and acute kidney injury: A pharmacovigilance study","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12944-024-02294-8","article-title":"Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: The NHANES 1999-2018 study","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/dom.15650","article-title":"Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials","volume":"26","author":"Leiter","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000549898","article-title":"Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience","volume":"16","author":"Franculli","year":"2026","journal-title":"Cardiorenal Med."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Zimodro, J.M., Rizzo, M., and Gouni-Berthold, I. (2025). Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18020147"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Rosca, C.I., Lighezan, D.F., Nisulescu, D.D., Sharma, A., Neagu, M.N., Nistor, D., Georgescu, D., and Kundnani, N.R. (2023). Metabolic Syndrome: A Strange Companion of Atrial Fibrillation; A Blessing in Disguise from the Neuropsychiatric Point of View. Biomedicines, 11.","DOI":"10.3390\/biomedicines11072012"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/14779072.2020.1768848","article-title":"Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia","volume":"18","author":"Nurmohamed","year":"2020","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e32818","DOI":"10.1097\/MD.0000000000032818","article-title":"Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study","volume":"102","author":"Iwasaki","year":"2023","journal-title":"Medicine"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1080\/14656566.2019.1649394","article-title":"Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease","volume":"20","author":"Katsiki","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Alhomoud, I.S. (2026). Current and Emerging Pharmacological Therapies for Hypertriglyceridemia. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27083573"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_161","first-page":"157","article-title":"Lipoprotein(a): Novel target and emergence of novel therapies to lower cardiovascular disease risk","volume":"24","author":"Tsimikas","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_162","first-page":"46","article-title":"Design and rationale of the Lp(a)HORIZON trial Genomics-informed drug-repurposing strategy identifies two therapeutic targets for preventing liver disease associated with metabolic dysfunction","volume":"248","author":"Nissen","year":"2022","journal-title":"Am. J. Hum. Genet."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an Extended\u2011Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose\u2011Ascending Clinical Trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"ref_164","first-page":"345","article-title":"The dedicated \u201cLp(a) clinic\u201d: A concept whose time has arrived?","volume":"45","author":"Tsimikas","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12933-026-03177-1","article-title":"Cardiovascular-kidney-metabolic syndrome: A comprehensive review of pathophysiology, epidemiology, diagnosis, and management","volume":"25","author":"Jankauskas","year":"2026","journal-title":"Cardiovasc Diabetol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clnesp.2020.03.003","article-title":"Effects of the Mediterranean diet on cardiovascular risk factors in non-alcoholic fatty liver disease patients: A systematic review and meta-analysis","volume":"37","author":"Asbaghi","year":"2020","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1601015","DOI":"10.1002\/mnfr.201601015","article-title":"TheMediterranean Diet decreases LDL atherogenicity in high cardiovascular risk individuals: A randomized controlled trial","volume":"61","author":"Goday","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_171","unstructured":"World Health Organization (2023). Cardiovascular Diseases (CVDs), WHO."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/S0140-6736(17)31634-3","article-title":"The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: The PURE study","volume":"390","author":"Lear","year":"2017","journal-title":"Lancet"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2018.14854","article-title":"The Physical Activity Guidelines for Americans","volume":"320","author":"Piercy","year":"2018","journal-title":"JAMA"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/CIRCRESAHA.118.313348","article-title":"The Mediterranean Diet and Cardiovascular Health","volume":"124","author":"Gea","year":"2019","journal-title":"Circ. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e2545232","DOI":"10.1001\/jamanetworkopen.2025.45232","article-title":"Concurrent Changes in Diet Quality and Physical Activity and Association with Adiposity in Adults","volume":"8","author":"Aryannezhad","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_176","first-page":"e984","article-title":"Obesity and cardiovascular disease: A scientific statement from the American Heart Association","volume":"143","author":"Poirier","year":"2021","journal-title":"Circulation"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s13679-023-00518-z","article-title":"Obesity and Dyslipidemia: A Review of Current Evidence","volume":"12","author":"Vekic","year":"2023","journal-title":"Curr. Obes. Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in obesity: Mechanisms and potential targets","volume":"5","author":"Klop","year":"2013","journal-title":"Nutrients"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"dgaa673","DOI":"10.1210\/clinem\/dgaa673","article-title":"Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis","volume":"105","author":"Hasan","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jacc.2019.11.046","article-title":"Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps: JACC State-of-the-Art Review","volume":"75","author":"Mechanick","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_182","unstructured":"US Department of Health and Human Services (2020). Smoking Cessation: A Report of the Surgeon General."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2010.09.023","article-title":"Effects of smoking and smoking cessation on lipids and lipoproteins: Outcomes from a randomized clinical trial","volume":"161","author":"Gepner","year":"2011","journal-title":"Am. Heart J."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0091-7435(03)00110-5","article-title":"The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: A meta-analysis","volume":"37","author":"Maeda","year":"2003","journal-title":"Prev. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1001\/jama.290.1.86","article-title":"Mortality risk reduction associated with smoking cessation in patients with coronary heart disease","volume":"290","author":"Critchley","year":"2003","journal-title":"JAMA"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","article-title":"Risk thresholds for alcohol consumption","volume":"391","author":"Wood","year":"2018","journal-title":"Lancet"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"d636","DOI":"10.1136\/bmj.d636","article-title":"Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: Systematic review and meta-analysis of interventional studies","volume":"342","author":"Brien","year":"2011","journal-title":"BMJ"},{"key":"ref_188","first-page":"e367","article-title":"Sleep duration and quality: Impact on lifestyle behaviors and cardiometabolic health","volume":"134","author":"Grandner","year":"2016","journal-title":"Circulation"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.2147\/IJGM.S563616","article-title":"Sleep and Cardiometabolic Health: A Narrative Review of Epidemiological Evidence, Mechanisms, and Interventions","volume":"18","author":"Direksunthorn","year":"2025","journal-title":"Int. J. Gen. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrcardio.2017.189","article-title":"Effects of stress on the development and progression of cardiovascular disease","volume":"15","author":"Steptoe","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_197","first-page":"1870","article-title":"Tirzepatide cardiovascular event risk assessment","volume":"27","author":"Sattar","year":"2021","journal-title":"Nat. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/03007995.2024.2442027","article-title":"Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: A meta-analysis and meta-regression of placebo controlled randomized controlled trials","volume":"41","author":"Rivera","year":"2025","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"103633","DOI":"10.1016\/j.amsu.2022.103633","article-title":"Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis","volume":"77","author":"Dar","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"101061","DOI":"10.1016\/j.ajpc.2025.101061","article-title":"Sodium-glucose cotransporter 2 inhibitors and atherosclerosis","volume":"23","author":"Ceasovschih","year":"2025","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_211","first-page":"165","article-title":"Cardiovascular-Kidney-Metabolic (CKM) Syndrome: New Developments in Symptoms, Diagnosis, and Treatment","volume":"10","author":"Cakmak","year":"2025","journal-title":"Gevher Nesibe J. Med. Health Sci."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Alyami, H., Alshuweishi, F.A., Baghdadi, N.A., Al-Sharafa, M.M., Jaber Alqahtani, A., and Alshuweishi, Y. (2026). Declining eGFR and Uremia Are Associated with Remnant Cholesterol Accumulation and Reduced HDL-C in Non-Dialysis Chronic Kidney Disease. J. Clin. Med., 15.","DOI":"10.3390\/jcm15082918"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/heartjnl-2017-312794","article-title":"Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease","volume":"104","author":"McClelland","year":"2018","journal-title":"Heart"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","article-title":"Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation","volume":"67","author":"Hoogeveen","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"112892","DOI":"10.1016\/j.exger.2025.112892","article-title":"Non-conventional lipid parameters predict the risk of rapid kidney function decline in patients with cardiovascular-kidney-metabolic syndrome: The first cohort study evidence from CHARLS","volume":"210","author":"Dong","year":"2025","journal-title":"Exp. Gerontol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"107473","DOI":"10.1016\/j.ahj.2026.107473","article-title":"CorCal Outcomes: A randomized trial using the pooled cohort equation or coronary artery calcium to select statin therapy in primary prevention patients. Study design and baseline characteristics","volume":"299","author":"Anderson","year":"2026","journal-title":"Am. Heart J."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"DA VINCI study. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of Lipid-Lowering Therapies over 2 Years in GOULD, a Registry of Patients with Atherosclerotic Cardiovascular Disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8317\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:26:42Z","timestamp":1790861202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":218,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188317"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188317","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}